Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression.
about
Matrin 3 is a co-factor for HIV-1 Rev in regulating post-transcriptional viral gene expressionThe basic domain of Rev from human immunodeficiency virus type 1 specifically blocks the entry of U4/U6.U5 small nuclear ribonucleoprotein in spliceosome assemblyHIV Rev-dependent binding of SF2/ASF to the Rev response element: possible role in Rev-mediated inhibition of HIV RNA splicingSpecific incorporation of heat shock protein 70 family members into primate lentiviral virionsIdentification of a Rev-related protein by analysis of spliced transcripts of the human endogenous retroviruses HTDV/HERV-KDifferential membrane binding of the human immunodeficiency virus type 1 matrix proteinRTE and CTE mRNA export elements synergistically increase expression of unstable, Rev-dependent HIV and SIV mRNAsCircularization of the HIV-1 RNA genomeInteractions between the HIV-1 Unspliced mRNA and Host mRNA Decay MachineriesFates of retroviral core components during unrestricted and TRIM5-restricted infectionSafety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adultsA third-generation lentivirus vector with a conditional packaging systemThe 5' RNA terminus of spleen necrosis virus contains a novel posttranscriptional control element that facilitates human immunodeficiency virus Rev/RRE-independent Gag production.HIV-1 requires Arf6-mediated membrane dynamics to efficiently enter and infect T lymphocytes.HIV-1 Env associates with HLA-C free-chains at the cell membrane modulating viral infectivity.Refinement of lentiviral vector for improved RNA processing and reduced rates of self inactivation repairMulti-Faceted Post-Transcriptional Functions of HIV-1 Rev.Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefitRefined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.Regulation of HIV-Gag expression and targeting to the endolysosomal/secretory pathway by the luminal domain of lysosomal-associated membrane protein (LAMP-1) enhance Gag-specific immune response.Particle size determinants in the human immunodeficiency virus type 1 Gag proteinControl of human immunodeficiency virus type 1 RNA metabolism: role of splice sites and intron sequences in unspliced viral RNA subcellular distribution.Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag geneBasic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA.A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene.Kinetic analysis of human immunodeficiency virus type 1 assembly reveals the presence of sequential intermediates.Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.The 5' RNA terminus of spleen necrosis virus stimulates translation of nonviral mRNATranslation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyproteinContributions of viral splice sites and cis-regulatory elements to lentivirus vector function.Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein.Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses.DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expressionLocalization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging.Nuclear RNA export and packaging functions of HIV-1 Rev revisitedGene therapy for infectious diseasesLong-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.Gammaretrovirus mRNA expression is mediated by a novel, bipartite post-transcriptional regulatory elementRU5 of Mason-Pfizer monkey virus 5' long terminal repeat enhances cytoplasmic expression of human immunodeficiency virus type 1 gag-pol and nonviral reporter RNA.
P2860
Q24315683-1FE04E8B-0566-468D-8B8F-7EF262384BD0Q24656044-8F4D05BA-9EFC-48B8-B2D1-8DCF123B2EFBQ24671943-255686CB-9CBB-4884-B446-0D19C2F6ACD0Q24674076-AFBF9BDC-6EFA-418F-B0EF-685799CDE977Q24678215-E22BF1D9-AF6E-4E79-8DD7-4EA139EAD5EBQ24679629-21980925-E5A0-48AD-A5D8-33B686201428Q25256626-38C982CE-BF1D-4735-AB10-F12AE619540CQ27481058-C2D93BCA-7C88-457D-8167-9B4031FD2691Q28078564-BB3C7A00-3988-4AAF-B4AB-FF1DF4C43D36Q28487732-4A487FAC-3907-4407-8EA9-53B5487CAE89Q28740321-0FF51026-D9E6-4F95-92E1-EA516740CB9DQ29616120-41DCAEA6-7DE4-4981-8E68-B392E8A80DFAQ30453503-4C1D7572-E5F1-455B-8F54-7914B4B18F82Q30499676-31B78BDC-067D-4749-813A-1DFC2433A11AQ30833678-D7F9FC27-FE9E-4140-B0EA-055C7A588244Q33509187-B88DA75D-617F-4F36-A3E2-D27EC30B56A8Q33565157-388606E1-2E21-4AE7-8325-8FD17258DA1BQ33698152-D773DDFC-F9F6-4BA4-A165-DCB405F9F479Q33721746-26444C9E-213C-464A-B25A-47AAC9611C84Q33763297-EFCF2A1A-AE5F-4D22-A26D-731F2BA475ABQ33783955-71B7E19C-8787-45FC-921B-F8A108E7F995Q33785931-FAE1291D-332A-49D1-9FD6-0546849B8BD7Q33799802-FE7A8B34-8F23-41E0-8B8C-F611C3D2C1CCQ33800960-8DF8E6D2-8EEB-4E5F-BB27-D29CB1E88F39Q33804963-B46D53F9-F665-47C3-96B1-9E688A88CC99Q33806395-073CC38E-542D-4C4D-9CB1-D5CDEDBBFEEAQ33806715-7D4E66CA-16C8-4E2B-AD50-F8638B18C4DDQ33810910-C75CE32D-E79B-4C13-B8B7-2B704E1F901EQ33814996-C19E9DC5-4523-4EF8-8BC7-7E7D3DA15E95Q33816167-0192F7FA-3460-4C6D-96DB-6F8415CF7EF0Q33820522-D5AC8645-2DA3-488D-A9D3-0F1B613824E8Q33822789-215381FB-AAC5-4589-91BF-4169D8C4364EQ33843297-D45896DA-36EE-4BA4-9BE8-0121BEF26078Q33851952-FD5E0B65-DBB4-4445-A343-FB1568697418Q33874415-E27AC7A4-3E17-4A03-AB51-992462C0A5B7Q33990559-6BCF5432-139E-4487-92A0-7F4EDECF1C75Q33992464-BF9118FC-1ED1-4485-BCA1-C521D4C68671Q34099837-0B44AE46-38D3-4F03-88E0-DD16D40F2435Q34248880-5363F271-F054-4DEC-B7DB-A57D42089D32Q34348421-026BA47E-52CA-4BEB-8215-6E8B8F8E6553
P2860
Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Mutational inactivation of an ...... ev-independent gag expression.
@ast
Mutational inactivation of an ...... ev-independent gag expression.
@en
type
label
Mutational inactivation of an ...... ev-independent gag expression.
@ast
Mutational inactivation of an ...... ev-independent gag expression.
@en
prefLabel
Mutational inactivation of an ...... ev-independent gag expression.
@ast
Mutational inactivation of an ...... ev-independent gag expression.
@en
P2093
P2860
P1433
P1476
Mutational inactivation of an ...... ev-independent gag expression.
@en
P2093
B K Felber
G N Pavlakis
G Nasioulas
J Harrison
M Campbell
S Schwartz
P2860
P304
P407
P577
1992-12-01T00:00:00Z